In a significant nod to its innovation and market impact, ACTO has been named one of Everest Group's Top 50™ Pharmaceutical Technology Providers for 2026. This recognition places the company among an elite group shaping the future of healthcare technology.

A Mark of Excellence

Everest Group's annual list highlights firms driving transformation in the pharmaceutical sector through cutting-edge solutions. ACTO's inclusion reflects its commitment to advancing how drug development and patient care are supported by technology.

Why It Matters

For pharma companies and investors, this list serves as a trusted benchmark. It signals which providers are not just keeping pace, but setting the tempo in a rapidly evolving industry. ACTO’s spot here suggests strong performance and potential for growth.

Looking Ahead

With 2026 on the horizon, this acknowledgment could bolster ACTO’s partnerships and client trust. It’s a testament to their team’s hard work and a beacon for what’s next in pharma tech.